InflaRx (IFRX) Stock Price, News & Analysis

Company Overview

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

Key Stats

• Today's Range: $0.82 to $0.87
• 50-Day Range: $0.73 to $1.85
• 52-Week Range: $0.71 to $2.82
• Volume: 350,495 shs
• Average Volume: 276,391 shs
• Market Capitalization: $55.73 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.60
• Consensus Rating: Buy

InflaRx Stock Analysis - MarketRank™

InflaRx scored higher than 79% of companies evaluated by MarketBeat, and ranked 189th out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Buy

Consensus Rating

InflaRx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

InflaRx has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for InflaRx are expected to decrease in the coming year, from ($1.04) to ($1.16) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of InflaRx is -0.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of InflaRx is -0.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

InflaRx has a P/B Ratio of 0.44. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.77% of the float of InflaRx has been sold short.

Short Interest Ratio / Days to Cover

InflaRx has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in InflaRx has recently decreased by 12.20%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

InflaRx does not currently pay a dividend.

Dividend Growth

InflaRx does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.77% of the float of InflaRx has been sold short.

Short Interest Ratio / Days to Cover

InflaRx has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in InflaRx has recently decreased by 12.20%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 1.44

News Sentiment

InflaRx has a news sentiment score of 1.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for InflaRx this week, compared to 2 articles on an average week.

Search Interest

2 people have searched for IFRX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added InflaRx to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, InflaRx insiders have not sold or bought any company stock.

Percentage Held by Insiders

16.30% of the stock of InflaRx is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

42.39% of the stock of InflaRx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

IFRX Stock Analysis - Frequently Asked Questions

How have IFRX shares performed this year?

InflaRx's stock was trading at $2.47 on January 1st, 2025. Since then, IFRX stock has decreased by 66.4% and is now trading at $0.8301.
View the best growth stocks for 2025 here.

How were InflaRx's earnings last quarter?

InflaRx (NASDAQ:IFRX) announced its earnings results on Wednesday, May, 7th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.18) by $0.04. The firm had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.03 million. InflaRx had a negative trailing twelve-month return on equity of 65.98% and a negative net margin of 33,362.70%.

When did InflaRx IPO?

InflaRx (IFRX) raised $100 million in an initial public offering on Wednesday, November 8th 2017. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO.

Who are InflaRx's major shareholders?

Top institutional investors of InflaRx include 683 Capital Management LLC (3.91%), Woodline Partners LP (1.12%), DAFNA Capital Management LLC (0.67%) and XTX Topco Ltd (0.06%).

How do I buy shares of InflaRx?

Shares of IFRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of InflaRx own?

Based on aggregate information from My MarketBeat watchlists, some other companies that InflaRx investors own include G1 Therapeutics (GTHX), Xeris Biopharma (XERS), Bristol-Myers Squibb (BMY), Enterprise Products Partners (EPD), Exelixis (EXEL), Tesla (TSLA) and Alibaba Group (BABA).

Company Calendar

• Last Earnings: 5/07/2025
• Today: 6/08/2025
• Next Earnings (Estimated): 8/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:IFRX
• CIK: 1708688
• Web: www.inflarx.de
• Phone: 493641508180
• Fax: 49-36-4150-8181
• Employees: 60
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $6.60
• High Stock Price Target: $10.00
• Low Stock Price Target: $2.00
• Potential Upside/Downside: +695.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 5 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.82)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$46.18 million
• Net Margins: -33,362.70%
• Pretax Margin: -33,408.11%
• Return on Equity: -65.98%
• Return on Assets: -56.86%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.31
• Quick Ratio: 4.61

Sales & Book Value

• Annual Sales: $129.75 thousand
• Price / Sales: 429.49
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.89 per share
• Price / Book: 0.44

Miscellaneous

• Outstanding Shares: 67,133,000
• Free Float: 56,190,000
• Market Cap: $55.73 million
• Optionable: Optionable
• Beta: 1.29